Thus, our present study reveals likely mechanism-specific differences in ASM potency and acute tolerability in the AD-associated PSEN2-KO mouse that warrant more in-depth clinical study in genetically confirmed EOAD patients with seizures. This evidence concerns the gene PSEN2 and Alzheimer disease.